Offering finances studies, trials and technology platform development
By Devika Patel
Knoxville, Tenn., Jan. 30 - Dicerna Pharmaceuticals Inc. said it priced its $90 million initial public offering of stock with a $13.5 million greenshoe. The deal was announced Dec. 31.
The company will sell 6 million common shares at $15.00 apiece.
Jefferies LLC, Leerink Partners LLC, and Stifel, Nicolaus & Co., Inc. are the joint bookrunners.
Settlement is expected Feb. 4.
Proceeds will be used for preclinical studies and clinical trials, technology platform development, working capital and general corporate purposes.
The biopharmaceutical company is based in Watertown, Mass. It expects its shares will trade on the Nasdaq under the symbol "DRNA."
| Issuer: | Dicerna Pharmaceuticals Inc.
|
| Issue: | Common stock
|
| Amount: | $90 million
|
| Greenshoe: | $13.5 million
|
| Shares: | 6 million
|
| Price: | $15.00
|
| Warrants: | No
|
| Bookrunners: | Jefferies LLC, Leerink Partners LLC, and Stifel, Nicolaus & Co., Inc.
|
| Co-lead manager: | Robert W. Baird & Co. Inc.
|
| Announcement date: | Dec. 31
|
| Pricing date: | Jan. 30
|
| Settlement date: | Feb. 4
|
| Stock exchange: | Nasdaq: DRNA
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
